stoxline Quote Chart Rank Option Currency Glossary
ARCA biopharma, Inc. (ABIO)
1.63  -0.01 (-0.61%)    02-23 15:58
Open: 1.65
High: 1.65
Volume: 4,578
Pre. Close: 1.64
Low: 1.61
Market Cap: 24(M)
Technical analysis
2024-02-23 4:34:44 PM
Short term     
Mid term     
Targets 6-month :  1.95 1-year :  2.04
Resists First :  1.67 Second :  1.75
Pivot price 1.63
Supports First :  1.55 Second :  1.29
MAs MA(5) :  1.63 MA(20) :  1.63
MA(100) :  1.78 MA(250) :  1.94
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  49 D(3) :  51.7
RSI RSI(14): 47.8
52-week High :  2.26 Low :  1.55
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ ABIO ] has closed above bottom band by 48.9%. Bollinger Bands are 41.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.65 - 1.66 1.66 - 1.67
Low: 1.59 - 1.6 1.6 - 1.61
Close: 1.61 - 1.63 1.63 - 1.64
Company Description

ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial; and research collaboration with Colorado Prevention Center, the University of Colorado's Academic Research Organization to develop and commercialize Gencaro. The company was incorporated in 2004 and is headquartered in Westminster, Colorado.

Headline News

Sat, 24 Feb 2024
ARCA biopharma (NASDAQ:ABIO) Research Coverage Started at - AmericanBankingNEWS

Mon, 05 Feb 2024
Arca Biopharma: Cash will fund ops through mid-2025 – BizWest - The Business Journal of the Boulder Valley and ... - BizWest

Thu, 01 Feb 2024
ARCA biopharma Announces 2023 Financial Results - GlobeNewswire

Wed, 20 Dec 2023
We're Not Very Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Rate - Yahoo Finance

Thu, 19 Oct 2023
Arca narrows loss, continues to evaluate merger – BizWest - BizWest

Thu, 13 Jul 2023
We're Not Very Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Rate - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 15 (M)
Shares Float 9 (M)
Held by Insiders 1.2 (%)
Held by Institutions 51.8 (%)
Shares Short 188 (K)
Shares Short P.Month 195 (K)
Stock Financials
EPS -0.38
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.54
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -11.1 %
Return on Equity (ttm) -13.6 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.5
Qtrly Earnings Growth 0 %
Operating Cash Flow -5 (M)
Levered Free Cash Flow -4 (M)
Stock Valuations
PE Ratio -4.41
PEG Ratio 0
Price to Book value 0.63
Price to Sales 0
Price to Cash Flow -4.72
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android